Rosner M.H. Perazella M.A.

Acute kidney injury in patients with cancer.

N Engl J Med. 376: 1770-1781Humphreys B.D. Soiffer R.J. Magee C.C.

Renal failure associated with cancer and its treatment: an update.

J Am Soc Nephrol. 16: 151-161Gelfand S.L. Schell J.O. Eneanya N.D.

Palliative care in nephrology: the Work and the Workforce.

Adv Chronic Kidney Dis. 27: 350-355Abdel-Kader K. Unruh M.L. Weisbord S.D.

Symptom burden, depression, and quality of life in chronic and end-stage kidney disease.

Clin J Am Soc Nephrol. 4: 1057-1064Bubis L.D. Davis L. Mahar A. et al.

Symptom burden in the first Year after cancer Diagnosis: an Analysis of patient-Reported outcomes.

J Clin Oncol. 36: 1103-1111Davison S.N. Koncicki H. Brennan F.

Pain in chronic kidney disease: a scoping review.

Semin Dial. 27: 188-204Weisbord S.D. Fried L.F. Mor M.K. et al.

Renal provider recognition of symptoms in patients on maintenance hemodialysis.

Clin J Am Soc Nephrol. 2: 960-967Laugsand E.A. Sprangers M.A. Bjordal K. Skorpen F. Kaasa S. Klepstad P.

Health care providers underestimate symptom intensities of cancer patients: a multicenter European study.

Health Qual Life Outcomes. 8: 104Koncicki H.M. Unruh M. Schell J.O.

Pain management in CKD: a guide for nephrology providers.

Am J Kidney Dis. 69: 451-460Ravel V. Ahmadi S.F. Streja E. et al.

Pain and kidney function decline and mortality: a cohort study of US veterans.

Am J Kidney Dis. 68: 240-246Davison S.N. Tupala B. Wasylynuk B.A. Siu V. Sinnarajah A. Triscott J.

Recommendations for the care receiving conservative kidney management.

Clin J Am Soc Nephrol. 14: 626-634

Efficacy of the world health organization analgesic ladder to treat pain in end-stage renal disease.

J Am Soc Nephrol. 17: 3198-3203Kimmel P.L. Fwu C.W. Abbott K.C. Eggers A.W. Kline P.P. Eggers P.W.

Opioid Prescription, morbidity, and mortality in United States dialysis patients.

J Am Soc Nephrol. 28: 3658-3670Cuomo A. Bimonte S. Forte C.A. Botti G. Cascella M.

Multimodal approaches and tailored therapies for pain management: the trolley analgesic model.

J Pain Res. 12: 711-714

Opioid analgesics adverse effects: the other side of the Coin.

Curr Pharm Des. 25: 3197-3202Ishida J.H. McCulloch C.E. Steinman M.A. Grimes B.A. Johansen K.L.

Opioid analgesics and adverse outcomes among hemodialysis patients.

Clin J Am Soc Nephrol. 13: 746-753Gelfand S.L. Juurlink D.N.

Pain region. NephMadness.

Chino F.L. Kamal A. Chino J.P.

Opioid-associated deaths in patients with cancer: a population study of the opioid epidemic over the past 10 years.

J Clin Oncol. 36: 230Mueller S.R. Walley A.Y. Calcaterra S.L. Glanz J.M. Binswanger I.A.

A review of opioid Overdose prevention and naloxone prescribing: Implications for Translating community Programming into clinical Practice.

Subst Abus. 36: 240-253Haroutiunian S. Drennan D.A. Lipman A.G.

Topical NSAID therapy for musculoskeletal pain.

Pain Med. 11: 535-549Dreischulte T. Morales D.R. Bell S. Guthrie B.

Combined use of nonsteroidal anti-inflammatory drugs with diuretics and/or renin-angiotensin system inhibitors in the community increases the risk of acute kidney injury.

Kidney Int. 88: 396-403Sriperumbuduri S. Hiremath S.

The case for cautious consumption: NSAIDs in chronic kidney disease.

Curr Opin Nephrol Hypertens. 28: 163-170

NSAIDs in CKD: are they Safe?.

Am J Kidney Dis. 76: 546-557

Can NSAIDs be used safely for analgesia in patients with CKD?.

CON Kidney360. 1: 1189-1191Lussier D. Huskey A.G. Portenoy R.K.

Adjuvant analgesics in cancer pain management.

Oncologist. 9: 571-591

Acetaminophen in patients receiving strong opioids for cancer pain.

J Pain Palliat Care Pharmacother. 34: 197-202American Geriatrics Society Panel on Pharmacological Management of Persistent Pain in Older Persons

Pharmacological management of persistent pain in older persons.

J Am Geriatr Soc. 57: 1331-1346Rakoski M. Goyal P. Spencer-Safier M. Weissman J. Mohr G. Volk M.

Pain management in patients with cirrhosis.

Clin Liver Dis. 11: 135-140

Drug information for infants, children, and adults.

Effectiveness of antiepileptic or antidepressant drugs when added to opioids for cancer pain: systematic review.

Palliat Med. 25: 553-559Finnerup N.B. Sindrup S.H. Jensen T.S.

The evidence for pharmacological treatment of neuropathic pain.

Pain. 150: 573-581

Analgesic Mechanisms of antidepressants for neuropathic pain.

Int J Mol Sci. 18: 2483Backonja M. Beydoun A. Edwards K.R. et al.

Gabapentin for the symptomatic treatment of painful neuropathy in patients with diabetes mellitus: a randomized controlled trial.

JAMA. 280: 1831-1836Raouf M. Atkinson T.J. Crumb M.W. Fudin J.

Rational dosing of gabapentin and pregabalin in chronic kidney disease.

J Pain Res. 10: 275-278Gelfand S.L. Scherer J.S. Koncicki H.M.

Kidney supportive care: Core Curriculum 2020.

Am J Kidney Dis. 75: 793-806Mercadante S.L. Berchovich M. Casuccio A. Fulfaro F. Mangione S.

A prospective randomized study of corticosteroids as adjuvant drugs to opioids in advanced cancer patients.

Am J Hosp Palliat Care. 24: 13-19

Early use of systemic corticosteroids in patients with advanced NSCLC treated with Nivolumab.

J Thorac Oncol. 13: 1771-1775Hwang S.S. Chang V.T. Rue M. Kasimis B.

Multidimensional independent predictors of cancer-related fatigue.

J Pain Symptom Manage. 26: 604-614Crawford J. Cella D. Cleeland C.S. et al.

Relationship between changes in hemoglobin level and quality of life during chemotherapy in anemic cancer patients receiving epoetin alfa therapy.

Cancer. 95: 888-895Leyland-Jones B. Bondarenko I. Nemsadze G. et al.

A randomized, open-label, multicenter, phase III study of epoetin alfa versus best standard of care in anemic patients with metastatic breast cancer receiving standard chemotherapy.

J Clin Oncol. 34: 1197-1207Bohlius J. Bohlke K. Castelli R. et al.

Management of cancer-associated anemia with erythropoiesis-stimulating agents: ASCO/ASH clinical Practice Guideline update.

J Clin Oncol. 37: 1336-1351Tarricone R. Ricca G. Nyanzi-Wakholi B. Medina-Lara A.

Impact of cancer anorexia-cachexia syndrome on health-related quality of life and resource utilisation: a systematic review.

Crit Rev Oncol Hematol. 99: 49-62Theobald D.E. Kirsh K.L. Holtsclaw E. Donaghy K. Passik S.D.

An open-label, crossover trial of mirtazapine (15 and 30 mg) in cancer patients with pain and other distressing symptoms.

J Pain Symptom Manag. 23: 442-447Aisner J. Parnes H. Tait N. et al.

Appetite stimulation and weight gain with megestrol acetate.

Semin Oncol. 17: 2-7Loprinzi C.L. Kugler J.W. Sloan J.A. et al.

Randomized comparison of megestrol acetate versus dexamethasone versus fluoxymesterone for the treatment of cancer anorexia/cachexia.

J Clin Oncol. 17: 3299-3306Naing A. Dalal S. Abdelrahim M. et al.

Olanzapine for cachexia in patients with advanced cancer: an exploratory study of effects on weight and metabolic cytokines.

Support Care Cancer. 23: 2649-2654Jatoi A. Windschitl H.E. Loprinzi C.L. et al.

Dronabinol versus megestrol acetate versus combination therapy for cancer-associated anorexia: a North Central Cancer Treatment Group study.

J Clin Oncol. 20: 567-573Navari R.M. Einhorn L.H. Passik S.D. et al.

A phase II trial of olanzapine for the prevention of chemotherapy-induced nausea and vomiting: a Hoosier Oncology Group study.

Support Care Cancer. 13: 529-534Garcia J.M. Li H. Mann D. et al.

Hypogonadism in male patients with cancer.

Cancer. 106: 2583-2591Thirumavalavan N. Wilken N.A. Ramasamy R.

Hypogonadism and renal failure: an update.

Indian J Urol. 31: 89-93Mohamed O. Freundlich R.E. Dakik H.K. et al.

The quantitative ADAM questionnaire: a new tool in quantifying the severity of hypogonadism.

Int J Impot Res. 22: 20-24Peuckmann V. Elsner F. Krumm N. Trottenberg P. Radbruch L.

Pharmacological treatments for fatigue associated with palliative care.

Cochrane Database Syst Rev. : CD006788Hedayati S.S. Yalamanchili V. Finkelstein F.O.

A practical approach to the treatment of depression in patients with chronic kidney disease and end-stage renal disease.

Kidney Int. 81: 247-255Ng C.G. Boks M.P. Zainal N.Z. De Wit N.J.

The prevalence and pharmacotherapy of depression in cancer patients.

J Affect Disord. 131: 1-7

Edema of advanced cancer: prevalence, etiology, and conservative management: a single hospice cross-sectional study.

. 57: 311-318Paladino J. Lakin J.R. Sanders J.J.

Communication strategies for sharing prognostic information with patients: beyond survival statistics.

JAMA. 322: 1345-1346

End of life care preferences and needs: perceptions of patients with chronic kidney disease.

Clin J Am Soc Nephrol. 5: 195-204Lim W.H. Au E. Krishnan A. Wong G.

Assessment of kidney transplant suitability for patients with prior cancers: is it time for a rethink?.

Transpl Int. 32: 1223-1240Perazella M.A. Sprangers B.

AKI in patients recieiving immune checkpoint inhibitors.

Clin J Am Soc Nephrol. 14: 1077-1079Grubbs V. Moss A.H. Cohen L.M. et al.

A palliative approach to dialysis care: a patient-centered transition to the end of life.

Clin J Am Soc Nephrol. 9: 2203-2209

Challenges with providing hospice care for patients undergoing long-term dialysis.

Clin J Am Soc Nephrol. 16: 473-475